We are pleased to announce the candidates for the position of President-Elect (2024, President 2025-2028):
The elections will be held online June 1 – June 30.
We invite all EAS members to take part in the life of the Society by using their vote.
Thank you in advance for your participation!
Professor Maciej Banach
Head of the Department of Preventive Cardiology and Lipidology at the Medical University of Lodz,
Adjunct Professor at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease
Prof Banach worked for the EAS as an Advisor in Matters related to EU Relations and he now serves as an EAS Secretary. He is a member of the Scientific and Health Policy Advisory Group of FH Europe, President of the Polish Lipid Association, Head of the Lipid and Blood Pressure Meta-analysis Collaboration Group, and of the International Lipid Expert Panel. Prof Banach has published >1400 papers with 62,175 citations (HI=83; Web of Science) and 102,073 (HI=109; Google Scholar) – being within the top highest cited scientists in the world according to Essential Science Indicators (Clarivate culmulative citation rank tool) with 59 TOP Papers. He is a laureate of numerous awards, including Doctor Honoris Causa (DHC) of the University in Zagreb, DHC of the Medical University in Bucharest, being in the top 10 on the TOP-100 List of the most influential scientists in medicine in Poland in last 5 years, “Gold Scalpel” Distinction for the Innovation/Smart Hospital, DHC of the Institute of Cardiology in Kiev, and others.
Short Vision
The following words express my vision for the EAS Presidency – people, science, passion, quality. I want EAS to be closer to the people involved in cardiovascular prevention and atherosclerosis. Not only physicians, but also nurses, dietitians, pharmacists and especially patients, by enhancing the existing collaboration with FH-Europe and other patient organizations.
- I will further develop existing initiatives, including the Lipid Clinic Network with the immediate inclusion of new centers to learn and exchange experience, and extend the EAS advanced courses and certification for all medical groups.
- Following the success of the FHSC/HICC, I will start the registries of other rare diseases, where our knowledge is limited (FCS, sitosterolemia, LAL-deficiency and others).
- I will focus on close and effective collaboration with National Societies to have them directly involved in the Society activities, to have regular meetings, to give them the representative roles within the activities and the EAS Congress, to involve them in the practical guidance papers, and to support them to improve the availability of diagnostic methods and drugs.
- I will create numerous opportunities for young people, with new dedicated grants for research and implementation science, to allow them to gain experience in the best European centers, to find the best mentors, to establish their first research team and to learn how to be a mentor from the outset.
- I will create new grants for researchers and National Societies to try to overcome inequalities and underrepresentation, and especially to facilitate the best research projects and organizational initiatives (surveys, meetings, actions).
- I will monitor the biggest problems of daily clinical work and develop practical recommendations to be applied in clinical practice. Whilst maintaining the highest quality and standards, and collaboration with other leading scientific societies, I will extend an open invitation to all EAS members to participate in a transparent list of guidelines in development.
- I propose 14th of November as World Dyslipidemia Day – the birthday of Prof Akira Endo who invented statins.
As those who know me hear often – this is just the beginning.
Let’s make the EAS our Family Society!
Current Positions
(Information on all positions, both within companies and other Societies)
Companies
- Chief Medical Officer at Nomi Biotech Corporations (till December 2022)
- Chief Medical and Development Officer in the Longevity Group/Longevity Center
Other societies
- Polish Lipid Association (President)
- International Lipid Expert Panel (Head)
- Lipid and Blood Pressure Meta-analysis Collaboration Group (Head)
- Thank-Thank Innovations for Health (President)
- European Atherosclerosis Society (Secretary)
- FH Europe (Member of the Scientific and Health Policy Advisory Group)
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content.
Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure form
Professor Børge G Nordestgaard
Copenhagen University Hospital, University of Copenhagen, Copenhagen (Denmark)
Academic Leadership
I have extensive knowledge of the EAS, joining aged 31, attending numerous congresses with invited presentations, including plenary lectures and the 2022 Anitschkow lecture. I served on EAS Executive Committees (1998-2001 and 2013-2016), organizing activities, including Consensus Papers (first author on 3 and co-author on 11). My H-index is 148 (Web of Knowledge and Scopus), and since 2015-2022 I was ranked among the top 0.1% highly cited researchers globally (http://highlycited.com/), with 900 original articles and 140 other publications. Through academic excellence and a clear track record of mentorship (71 successful Ph.D.-students, 34 postdocs, and 50 other young scientists) I am ideally placed to nurture the independent researchers of tomorrow.
International Network
International collaboration is essential for the EAS and I will expand and strengthen my existing collaborations across Europe, North America, Asia, Australia, Africa, and Latin America and see what the EAS can do for you wherever you are.
I am ideally connected to leverage good working relations with major players within atherosclerosis research and clinical implementation, including those within US (AHA, ACC, NLA, ADA, and AACC), Europe (ESC and EFLM), and the IAS, having been invited to participate in 3 US-based, 3 other European-based, and 2 international-based consensus statements.
Collaboration without personal financial interests is important for the EAS and I will bring an existing, extensive network of 10+ pharmaceutical industries who I have collaborated with extensively over two decades to see how industry and academia can further work together to benefit patients.
Organization and Communication
I have extensive experience as Chairman/President of the Scandinavian Atherosclerosis Society at age 36 and contributed to the organization of 10 European and 3 US congresses. Further, I have organized the Copenhagen General Population Study with >160,000 participants and run a large and successful research group in Copenhagen. If elected, I will not only work hard for you, but be the person I have been throughout my life, straight forward and honest, an essential characteristic for leading the EAS with transparency and integrity.
My vision
My passion for the EAS runs deep. Everybody interested in atherosclerosis should be part of our society, whether they are in clinical work, basic research, clinical research, implementation, industry, patient organization, medical regulation, publishing or media, irrespective of gender, age, ethnicity, country, religion, and gender identity. We can all contribute equally to the success of the EAS and I hope to involve as many of you as possible in EAS activities.
Together we can further develop our society in high-quality research, implementation, training of clinicians, clinical guidelines, global outreach, and inclusion of all those interested. We will nurture young talent, create collaborations, and develop future leaders, jointly with all national and other societies affiliated with the EAS.
Personally, I want to give back broadly to the society that has given me so much, and I will make time to continue the progress for a financially strong, stable professional society fit for the future. I dream of our EAS to represent the very best and for everybody.
Current positions
(Information on all positions, both within companies and other Societies)
Companies
- None
Other Societies
- None
Maintaining Integrity in EAS Scientific and Clinical Activities
EAS manages conflicts of interest to maintain integrity in scientific and clinical activities organized by its members. This includes guidelines, consensus papers, journals, congresses, and educational content. Please see the complete disclosure of potential conflicts of interest below.
Log in to view full COI disclosure